Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
32
OZEM Quote, Financials, Valuation and Earnings
Last price:
$24.80
Seasonality move
:
--
Day range:
$24.60 - $24.82
52-week range:
$24.33 - $29.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
14.2K
Avg. volume:
29K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$24.73 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$27.21 | -- | -- | -- | $0.13 | 1.65% | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
$32.61 | -- | -- | -- | $0.01 | 0.02% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.82 | -- | -- | -- | $0.06 | 1.13% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$23.11 | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.000 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | 1.154 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.252 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
Roundhill GLP-1 & Weight Loss ETF vs. Competitors
-
Which has Higher Returns OZEM or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is OZEM or FTXH More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.13 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or FTXH?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns OZEM or GDOC?
Goldman Sachs Future Health Care Equity ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Goldman Sachs Future Health Care Equity ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -
What do Analysts Say About OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Goldman Sachs Future Health Care Equity ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Goldman Sachs Future Health Care Equity ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Goldman Sachs Future Health Care Equity ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 -
Is OZEM or GDOC More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Goldman Sachs Future Health Care Equity ETF offers a yield of 0.02% to investors and pays a quarterly dividend of $0.01 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Goldman Sachs Future Health Care Equity ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or GDOC?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Goldman Sachs Future Health Care Equity ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Goldman Sachs Future Health Care Equity ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Goldman Sachs Future Health Care Equity ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Goldman Sachs Future Health Care Equity ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- --
-
Which has Higher Returns OZEM or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is OZEM or IBBQ More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.13% to investors and pays a quarterly dividend of $0.06 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or IBBQ?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns OZEM or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Roundhill GLP-1 & Weight Loss ETF's net margin of --. Roundhill GLP-1 & Weight Loss ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Roundhill GLP-1 & Weight Loss ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Roundhill GLP-1 & Weight Loss ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is OZEM or THNR More Risky?
Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roundhill GLP-1 & Weight Loss ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OZEM or THNR?
Roundhill GLP-1 & Weight Loss ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Roundhill GLP-1 & Weight Loss ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Roundhill GLP-1 & Weight Loss ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roundhill GLP-1 & Weight Loss ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 6.52% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.58% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 0.46% over the past day.
